E.E. Geduld’s Aclaris Therapeutics ACRS Stock Holding History

E.E. Geduld’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.22M	Buy	45,061 +22,561	+100%	+$575K	0.69%	11
2016 Q3	$576K	Buy	22,500 +5,000	+29%	+$106K	0.57%	32
2016 Q2	$323K	Buy	17,500 +6,729	+62%	+$133K	0.42%	45
2016 Q1	$204K	Sell	10,771 -2,229	-17%	-$42.6K	0.28%	63
2015 Q4	$350K	Buy	+13,000	New	+$253K	0.22%	51

Other funds holding ACRS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

SMV

Sofinnova Management VIII Menlo Park, California $183M AUM 4.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

E.E. Geduld's ACRS Position: Q4 2016 in Review

E.E. Geduld increased its Aclaris Therapeutics (ACRS) stake by 100% in Q4 2016, buying an estimated $575K and bringing the position to 45,061 shares worth $1.22M. The position accounts for 0.69% of the portfolio, ranked #11.

E.E. Geduld first reported a position in ACRS in Q4 2015 and has held it in 5 quarters since. 100 funds tracked by Wall St. Rank hold ACRS as of Q4 2016.

E.E. Geduld held 45,061 shares of Aclaris Therapeutics worth $1.22M as of Q4 2016.
E.E. Geduld bought 22,561 Aclaris Therapeutics shares in Q4 2016, an estimated $575K.
Aclaris Therapeutics made up 0.69% of E.E. Geduld's portfolio in Q4 2016, its #11 holding.
E.E. Geduld first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 5 quarters since.
100 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.